T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public Neoantigen.
Cancer Immunol Res
; 10(8): 919, 2022 08 03.
Article
em En
| MEDLINE
| ID: mdl-35767244
ABSTRACT
T-cell receptors (TCR) are an antigen receptor class that can uniquely respond to epitopes resulting from cytosolic and intranuclear proteins. In this issue, Kim and colleagues report the first successful application of TCR gene therapy targeting a shared, or public, neoantigen resulting from a TP53 hotspot mutation. These results establish clinical proof of concept that an off-the-shelf TCR targeting a recurrent mutation in a molecular driver of oncogenesis can benefit patients with metastatic cancer. See related article by Kim et al., p. 932 (4) .
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Linfócitos do Interstício Tumoral
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Cancer Immunol Res
Ano de publicação:
2022
Tipo de documento:
Article